Heres some info, thoughts on it?Hope we get some news soon. I have been trying to find info on some of the questions I have had with this company and here is what I have so far.
As for the question of the licence they are purchasing not a lot of info on the company but I found this document.
NAME CHANGE December 24, 2015, Vancouver, BC – Seashore Organic Medicine Inc. (“SOM” or the “Company”) (CSE: SOM) announces that it will change its name to Veritas Pharma Inc. (the "Name Change"). The Name Change will be effective at the open of December 29, 2015. The Company's common shares will begin trading on the Canadian Securities Exchange (the "CSE") under the new name, Veritas Pharma Inc., and under the symbol of "VRT". No other change has been made to the Company's share capital. Disclosure documents are available on the CSE website. About Seashore Organic Medicine Seashore Organic Medicine is a Canadian Securities Exchange (CSE) listed company based in Sechelt, British Columbia. Through its wholly owned subsidiary, Sechelt Organic Marijuana Corp., has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. On behalf of the Board of Directors SEASHORE ORGANIC MEDICINE INC. "Dr. Lui Franciosi" Dr. Lui Franciosi Chief Executive Officer Further information about the Company is
Notice the owner of the licence. They are buying the licence from themselves? This part confuses me but my next question is when the hell is the licence going to get approved and whey is it taking so long?
An update on this is going to go a long way I am hoping with some positve news.
October 4, 2016, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces that it has received a quarterly research report from Cannevert Therapeutics Limited (CTL), lead researcher for Veritas. The report outlines both general and scientific progress since their last update.
Overall, CTL is a fully functional research company able to efficiently determine the amounts of cannabinoids present in different cultivars with precision and accuracy. This is to confirm that the materials received from cannabis suppliers have the purported characteristics, especially the cannabinoids of interest. In their initial animal studies, CTL has identified a number of cultivars with analgesic actions. They are now performing secondary screening, in particular, the collection of dose-response data for all pharmacological types of actions. The company continues to source more strains across Canada with potential therapeutic characteristics of interest. From a finance perspective, it has been fiscally responsible while ensuring that a six-month operational window is in place at all times. It’s funding has been improved by obtaining grants to help reduce research costs for personnel salaries. It has now accumulated a total of 16 committed personnel, comprising faculty, research associates, postdoctoral fellows, graduate students and co-op students. For the remainder of the year, Cannevert aims to acquire more skilled workers, identify further appropriate cultivars or mixtures of cultivars with therapeutic potential, and initiate planning for future clinical trials.
Veritas CEO, Dr. Lui Franciosi, stated “Cannevert research experiments have greatly progressed in both capacity and sophistication. I am impressed by the quality of the research and the team’s expanding capabilities. I believe we have made substantial gains in both developing the required infrastructure (facilities and personnel) and in our actual work to deliver on Veritas goals and timelines.”
All in all I have quite a bit riding on this company and am hoping for some upward movment and positive news in the short run because last couple of weeks the share price has been hit. Thoughts? comments? news? anyone?